Q3 2025 Financial Performance - Revenue for Q3 2025 was $634.5 million, compared to $687.5 million in Q3 2024, a decrease of 7.7%[9] - Gross profit for Q3 2025 was $184.4 million, with a gross margin of 29.1%, compared to $213.1 million and 31.0% respectively in Q3 2024[9] - Operating income for Q3 2025 was $47.6 million, resulting in an operating margin of 7.5%, compared to $22.3 million and 3.2% respectively in Q3 2024[9] - Net income for Q3 2025 was $29.3 million, or $0.76 per share, compared to $7.0 million, or $0.18 per share in Q3 2024[9] - Adjusted EBITDA for Q3 2025 was $57.5 million, with an adjusted EBITDA margin of 9.1%, compared to $73.9 million and 10.7% respectively in Q3 2024[9] Segment Performance - Nurse & Allied Solutions revenue was $361 million in Q3 2025, a 9.5% decrease year-over-year[9] - Physician & Leadership Solutions revenue was $175 million in Q3 2025, a 1.3% decrease year-over-year[9] - Technology & Workforce Solutions revenue was $95 million in Q3 2025, an 11.8% decrease year-over-year[9] Balance Sheet and Cash Flow - Cash and cash equivalents totaled $53 million as of September 30, 2025, compared to $42 million as of June 30, 2025[35] - Net cash provided by operating activities was $23 million in Q3 2025, compared to $67 million in Q3 2024[37] - Free cash flow was $15 million in Q3 2025, compared to $47 million in Q3 2024[37] Q4 2025 Financial Guidance - Consolidated revenue is projected to be between $715 million and $730 million[39] - Gross margin is expected to be between 25.5% and 26.0%[39] - Adjusted EBITDA margin is projected to be between 6.8% and 7.3%[39]